Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
56 drugs in development
By Therapeutic Area
top 6
R&D Momentum
96/100
Pipeline Velocity
72/100
Trial Completion Rate
88/100
Pipeline Concentration
24/100
Pipeline Freshness
11/100
Strategic Signals
Activity
Last 14 days
A Pilot Study to Evaluate the Safety and Tolerability of Baricitinib in Patients With Job s Syndrome With Lupus-like Disease and/or Atopic Dermatitis
Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
A Phase I/II, Non-Randomized, Open-Label Study of pCCLCHIM-p47 (Lentiviral Vector Transduced CD34+ Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)
The Natural History of Severe Viral Infections and Characterization of Immune Defects
Modeling Host-Pathogen Interaction Using Lymphoid Organoids
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
Metabolic Profiling of Immune Responses in Immune-Mediated Diseases
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
A Phase 2a Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)